170 related articles for article (PubMed ID: 35099990)
21. Inactivated vaccine effectiveness against symptomatic COVID-19 in Fujian, China during the Omicron BA.2 outbreak.
Ye W; Li K; Zhao Z; Wu S; Qu H; Guo Y; Abudunaibi B; Chen W; Cai S; Chen C; Lin J; Xie Z; Zhan M; Ou J; Deng Y; Chen T; Zheng K
Front Public Health; 2023; 11():1269194. PubMed ID: 38162626
[TBL] [Abstract][Full Text] [Related]
22. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study.
Chia PY; Ong SWX; Chiew CJ; Ang LW; Chavatte JM; Mak TM; Cui L; Kalimuddin S; Chia WN; Tan CW; Chai LYA; Tan SY; Zheng S; Lin RTP; Wang L; Leo YS; Lee VJ; Lye DC; Young BE
Clin Microbiol Infect; 2022 Apr; 28(4):612.e1-612.e7. PubMed ID: 34826623
[TBL] [Abstract][Full Text] [Related]
23. Impact of inactivated COVID-19 vaccines on lung injury in B.1.617.2 (Delta) variant-infected patients.
Lai M; Wang K; Ding C; Yin Y; Lin X; Xu C; Hu Z; Peng Z
Ann Clin Microbiol Antimicrob; 2023 Mar; 22(1):22. PubMed ID: 36944961
[TBL] [Abstract][Full Text] [Related]
24. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021.
Machado A; Kislaya I; Rodrigues AP; Sequeira D; Lima J; Cruz C; Leite PP; Matias Dias C; Nunes B
PLoS One; 2022; 17(9):e0274008. PubMed ID: 36099273
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.
Desai D; Khan AR; Soneja M; Mittal A; Naik S; Kodan P; Mandal A; Maher GT; Kumar R; Agarwal A; Gowda NR; H V; Kumar P; Pandey S; Pandey RM; Kumar A; Ray A; Jorwal P; Nischal N; Choudhary A; Brijwal M; Madan K; Lodha R; Sinha S; Dar L; Wig N; Guleria R
Lancet Infect Dis; 2022 Mar; 22(3):349-356. PubMed ID: 34826383
[TBL] [Abstract][Full Text] [Related]
26. Real-World Effectiveness of Primary Series and Booster Doses of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2 Variant Infection in China: A Retrospective Cohort Study.
Tang L; Wang FZ; Rodewald LE; Wang XY; Liu SY; Liu QQ; Wang XQ; Wu D; Li MS; Zhang Q; Shao YM; Huang LF; Song YD; Huang Y; Zeng X; Liu LJ; Yang H; Huang AD; Bao LM; Zheng H; Ma C; Lv XY; Song L; Ma Z; Wang SG; Ma H; Guan WJ; Wu ZY; Zhong NS; Yin ZD
J Infect Dis; 2023 Aug; 228(3):261-269. PubMed ID: 37005365
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
[TBL] [Abstract][Full Text] [Related]
28. Real-World Evidence for COVID-19 Delta Variant's Effects on the Digestive System and Protection of Inactivated Vaccines from a Medical Center in Yangzhou, China: A Retrospective Observational Study.
Zhao W; Li Y; Xie R; Dong Y; Wei Y; Cheng C; Lowe S; Sun C; Wang C; Gao J
Int J Clin Pract; 2022; 2022():7405448. PubMed ID: 36052305
[TBL] [Abstract][Full Text] [Related]
29. Transmission and containment of the SARS-CoV-2 Delta variant of concern in Guangzhou, China: A population-based study.
Li L; Han ZG; Qin PZ; Liu WH; Yang Z; Chen ZQ; Li K; Xie CJ; Ma Y; Wang H; Huang Y; Fan SJ; Yan ZL; Ou CQ; Luo L
PLoS Negl Trop Dis; 2022 Jan; 16(1):e0010048. PubMed ID: 34986169
[TBL] [Abstract][Full Text] [Related]
30. SARS-CoV-2 Delta Variant Breakthrough Infection and Onward Secondary Transmission in Household.
Yi S; Kim JM; Choe YJ; Hong S; Choi S; Ahn SB; Kim M; Park YJ
J Korean Med Sci; 2022 Jan; 37(1):e12. PubMed ID: 34981682
[TBL] [Abstract][Full Text] [Related]
31. Urban monitoring, evaluation and application of COVID-19 listed vaccine effectiveness: a health code blockchain study.
Wang T; Li C; Li H; Li Z
BMJ Open; 2022 Jul; 12(7):e057281. PubMed ID: 35831042
[TBL] [Abstract][Full Text] [Related]
32. [Effect of inactivated SARS-CoV-2 vaccine on the clinical outcomes of patients infected with the Omicron variant in Guangdong Province].
Hu P; Lin DE; Zhu Q; Hu T; Zhang M; Zhang CQ; Sun LM; He JF
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Jul; 57(7):992-996. PubMed ID: 37482735
[No Abstract] [Full Text] [Related]
33. Transmission of and Infection With COVID-19 Among Vaccinated and Unvaccinated Attendees of an Indoor Wedding Reception in Minnesota.
Wienkes H; Vilen K; Lorentz A; Gerlach D; Wang X; Saupe A; Danila R; Lynfield R; Smith K; Medus C
JAMA Netw Open; 2022 Feb; 5(2):e220536. PubMed ID: 35212747
[TBL] [Abstract][Full Text] [Related]
34. Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study.
Barchuk A; Cherkashin M; Bulina A; Berezina N; Rakova T; Kuplevatskaya D; Stanevich O; Skougarevskiy D; Okhotin A
BMC Med; 2022 Sep; 20(1):312. PubMed ID: 36123681
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.
Griffin JB; Haddix M; Danza P; Fisher R; Koo TH; Traub E; Gounder P; Jarashow C; Balter S
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1170-1176. PubMed ID: 34437525
[TBL] [Abstract][Full Text] [Related]
36. Infection control, occupational and public health measures including mRNA-based vaccination against SARS-CoV-2 infections to protect healthcare workers from variants of concern: A 14-month observational study using surveillance data.
Yassi A; Grant JM; Lockhart K; Barker S; Sprague S; Okpani AI; Wong T; Daly P; Henderson W; Lubin S; Kim Sing C
PLoS One; 2021; 16(7):e0254920. PubMed ID: 34270608
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
38. Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants.
Trobajo-Sanmartín C; Martínez-Baz I; Miqueleiz A; Fernández-Huerta M; Burgui C; Casado I; Baigorría F; Navascués A; Castilla J; Ezpeleta C
Microbiol Spectr; 2022 Apr; 10(2):e0000822. PubMed ID: 35412379
[TBL] [Abstract][Full Text] [Related]
39. Continued effectiveness of COVID-19 vaccination among urban healthcare workers during delta variant predominance.
Lan FY; Sidossis A; Iliaki E; Buley J; Nathan N; Bruno-Murtha LA; Kales SN
BMC Infect Dis; 2022 May; 22(1):457. PubMed ID: 35549891
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of Inactivated Vaccine against SARS-CoV-2 Delta Variant Infection in Xiamen, China-A Test-Negative Case-Control Study.
He T; Wang M; Mi H; Xu L; Lu W; Ouyang X; Guo Z; Su C
Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
